Clinical Trial

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated February 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the safety and efficacy of the IL-22BP/LNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-21
Trial Details
NCT Number NCT07100210
Lead Sponsor Xingchen Peng
Conditions Refractory Malignant Solid Tumors, mRNA Vaccine, Interleukin
Enrollment 6 participants
Start Date 2025-01-20
Primary Completion 2026-02-20 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-29